DPP-4 inhibitors
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
DPP-4 inhibitors in the treatment of type 2 diabetes.
DPP-4 inhibitors
DPP-4 inhibitors
Auteur(s) :
Duez, Helene [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Cariou, Bertrand [Auteur]
ITX - unité de recherche de l'institut du thorax [ITX]
Staels, Bart [Auteur correspondant]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Cariou, Bertrand [Auteur]
ITX - unité de recherche de l'institut du thorax [ITX]
Staels, Bart [Auteur correspondant]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Titre de la revue :
Biochemical Pharmacology
Pagination :
823-32
Éditeur :
Elsevier
Date de publication :
2012-04-01
ISSN :
0006-2952
Mot(s)-clé(s) en anglais :
dipeptidylpeptidase (DPP)-4 inhibitors
gliptins
glucagon-like peptide (GLP)-1
glycemic control
type 2 diabetes
gliptins
glucagon-like peptide (GLP)-1
glycemic control
type 2 diabetes
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire
Résumé en anglais : [en]
Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered ...
Lire la suite >Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a ≥ 80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.Lire moins >
Lire la suite >Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a ≥ 80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Fichiers
- https://www.hal.inserm.fr/inserm-00659269/document
- Accès libre
- Accéder au document
- http://www.hal.inserm.fr/inserm-00659269/file/Duez_et_al._DPP4inhibitors_MStext.pdf
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-00659269/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-00659269/document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Duez_et_al._DPP4inhibitors_MStext.pdf
- Accès libre
- Accéder au document
- Duez_et_al._DPP4inhibitors_MStext.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Duez_et_al._DPP4inhibitors_MStext.pdf
- Accès libre
- Accéder au document